COOPER COS INC shareholders Q1 2023

COOPER COS INC's ticker is COO and the CUSIP is 216648402. A total of 563 filers reported holding COOPER COS INC in Q1 2023. The put-call ratio across all filers is 0.49 and the average weighting 0.2%.

COOPER COS INC shareholders Q1 2023
Name	Shares	Value	Weighting ↓
Veritas Asset Management LLP	2,088,761	$779,859,807	5.76%
Laurus Investment Counsel Inc.	31,380	$15,864,568	5.66%
Iron Triangle Partners LP	85,000	$31,735,600	4.58%
Parkman Healthcare Partners LLC	52,384	$19,558,090	4.25%
Crystal Rock Capital Management	13,545	$5,057,161	4.19%
Intermede Investment Partners Ltd	407,144	$152,011	3.72%
GENERATION INVESTMENT MANAGEMENT LLP	1,627,438	$607,620,251	3.24%
Handelsinvest Investeringsforvaltning	52,753	$19,696	3.14%
Close Asset Management Ltd	169,530	$63,271	3.13%
RBO & CO LLC	48,083	$17,952,269	3.13%
Integral Health Asset Management, LLC	40,000	$14,934,400	3.01%
Rhenman & Partners Asset Management AB	68,000	$24,987,960	2.74%
WD RUTHERFORD LLC	10,158	$3,792,591	2.67%
TAURUS ASSET MANAGEMENT, LLC	47,115	$17,590,856	2.15%
BRANT POINT INVESTMENT MANAGEMENT LLC	27,857	$10,400,690	1.73%
KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC	1,531,670	$571,864,419	1.68%
ArrowMark Colorado Holdings LLC	351,856	$131,368,956	1.49%
RMB Capital Management, LLC	104,321	$38,949,333	1.36%
BUCKHEAD CAPITAL MANAGEMENT LLC	14,695	$5,486,525	1.29%
Woodline Partners LP	242,047	$90,370,668	1.23%

About COOPER COS INC

Cooper Cos Inc is a global medical device company that specializes in the manufacturing and distribution of contact lenses, surgical instruments, and diagnostic products. The company has been in operation for over 60 years and has a strong reputation for innovation and quality.

Cooper Cos Inc has a diverse portfolio of products that cater to the needs of various healthcare professionals and patients. The company's contact lens division, CooperVision, is a leading provider of soft contact lenses and has a presence in over 100 countries. The surgical division, CooperSurgical, offers a range of products for gynecologists, obstetricians, and fertility specialists. The diagnostic division, CooperGenomics, provides genetic testing services for reproductive health and oncology.

The company's financial performance has been impressive in recent years, with revenue growth of 7% in 2020. The COVID-19 pandemic had a minimal impact on the company's operations, and it continued to invest in research and development to drive innovation.

Cooper Cos Inc has a strong leadership team, with Al White serving as the CEO and President. The company's board of directors includes experienced professionals from various industries, including healthcare, finance, and technology.

In conclusion, Cooper Cos Inc is a well-established medical device company with a diverse portfolio of products and a strong reputation for innovation and quality. The company's financial performance has been impressive, and it has a strong leadership team in place to drive future growth.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists COOPER COS INC's shareholders in Q1 2023. To view COOPER COS INC's shareholder history, click here.